Daiichi Sankyo settles its cardio drug lawsuit with Esperion, which will get $125M milestone payment

Dai­ichi Sankyo Eu­rope and Es­pe­ri­on Ther­a­peu­tics have agreed to a $125 mil­lion change to their col­lab­o­ra­tion agree­ment, set­tling a le­gal dis­pute that erupt­ed af­ter the tri­al read­out of the car­dio­vas­cu­lar drug on which they are part­nered.

The com­pa­nies an­nounced Wednes­day that Dai­ichi Sankyo would pay Es­pe­ri­on $100 mil­lion this month ahead of po­ten­tial ap­provals by the Eu­ro­pean Med­i­cines Agency for two car­dio­vas­cu­lar drugs: Nilem­do and Nus­ten­di (mar­ket­ed in the US as Nexle­tol and Nexl­izet, re­spec­tive­ly). Dai­ichi will al­so pay an ad­di­tion­al $25 mil­lion to Es­pe­ri­on in the quar­ter af­ter the EMA’s de­ci­sion on the pend­ing ap­pli­ca­tion for the drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.